Life
1 ‘Pawzempic’ Weight-Loss Drugs for Dogs and Cats May Be Coming Next
Biotech startups are racing to bring Ozempic-style weight-loss drugs to cats and dogs, promising slimmer pets — and raising questions about safety and cost for owners
ByBernadette Giacomazzo
July 22, <a href="https://healthylife7.com/2026-ifbb-pro-league-chicago-pro-winners/” title=”2026 IFBB Pro League Chicago Pro Winners”>2026
Key Takeaways
- Two biotech companies, Akston Biosciences and OKAVA Pharmaceuticals, are running early trials of once-weekly injections and a six-month implant GLP-1 treatment to tackle feline obesity, with no approved “Ozempic for pets” on the market yet.
- The drugs mimic hormones that curb appetite and slow digestion, aiming to address a massive problem as vets classify roughly 60% of U.S. cats and dogs as overweight or obese, a condition that shortens lifespans and strains joints and hearts.
- With human GLP-1 use booming and pet spending projected to top $240 billion by 2030, Wall Street sees a shift from premium kibble to full-on “medicalization” of pets, though analysts warn these animal GLP-1s may not match the runaway success of their human counterparts.
The GLP-1 craze may be coming for Fido and Fluffy next. Two U.S. biotech companies are testing weight-loss treatments for overweight cats, opening the door to a potential new era of prescription obesity medicine for animals
According to CNBC, Akston Biosciences is backing a Cornell University clinical trial of a once-weekly GLP-1 treatment involving about 70 overweight or obese cats. OKAVA Pharmaceuticals is taking a different approach with MEOW-1, a trial involving an implant designed to release medication for up to six months
Both companies expect initial results later this year, but the products would still need to clear additional safety and effectiveness hurdles before veterinarians could prescribe them
The market is not exactly small. In 2022, veterinary professionals classified 61 percent of cats and 59 percent of dogs they evaluated as overweight or obese. Those extra pounds can shorten an animal’s life and increase strain on its joints and heart
Unlike dogs, cats are particularly tough customers — longer walks are rarely a practical option, diet changes can be difficult and daily medication may turn into a full-contact sport
“Feline obesity is one of the most common yet least effectively treated health issues in veterinary medicine,” Akston CEO Todd Zion said when the company announced its trial
Like the medications used by humans, the experimental pet treatments are designed to regulate appetite by mimicking natural hormones that slow digestion and signal fullness
Human GLP-1 drugs have produced average weight reductions of 15 to 25 percent, though nausea, vomiting, diarrhea and weight regain after stopping treatment remain known concerns
The pet trials arrive as GLP-1 use explodes among people. 11 percent of U.S. adults reportedly now take the drugs for weight loss, while 18 percent have used one for weight loss, diabetes or another condition at some point
The medications have also expanded into treatments for sleep apnea, fatty liver disease and cardiovascular risk. Delivery methods now include weekly injections and daily pills
Pets could become the industry’s next frontier — but the price will matter. U.S. pet spending is projected to jump from roughly $196 billion in 2025 to more than $240 billion by 2030 as owners pour money into premium food, supplements, diagnostics and advanced veterinary care
Morgan Stanley analyst Simeon Gutman described the shift as an “expansion from premiumization into medicalization,” while warning that pet GLP-1s may not replicate the human market’s success
Related Stories
Life
7-Year-Old Indiana Girl Hospitalized After Injecting Herself With Mom’s GLP-1 Medication
The child was reportedly hospitalized after accidentally using her mother’s GLP-1 injector, a class of medications that includes Ozempic
Bernadette Giacomazzo169 days ago
Pop Culture
Vanessa Williams Opens Up About Using GLP-1 During Menopause: ‘Science Is Amazing’
The 62-year-old opens up about embracing medical options like GLP-1 medication and hormone therapy to support her aging journey
Bernadette Giacomazzo190 days ago
Pop Culture
Jameela Jamil Slams Serena Williams for GLP-1 Drug Use
‘Another reason we should take every celebrity endorsement with a pinch of salt,’ she said
Bernadette Giacomazzo331 days ago
Trending
1Pop CultureEverything You Missed From the New ‘Avengers: Doomsday’ Trailer
2Sneakers12 Individuals Indicted in $2 Million Nike Cargo Theft Scheme
3Pop CultureBlueface Admits to Cheating on Pregnant Girlfriend Nevaeh Akira With Chrisean Rock
4Pop CultureEvery Christopher Nolan Movie, Ranked From Worst to Best
5StyleAdidas Introduces Originals Sport Womenswear Collection With Tate McRae and Emilia Mernes
6Music50 Cent Mocks Rick Ross Over ‘Set in Stone’ Chart Projections: ‘It’s Over, Officer’
Editor’s Pick
MusicThe Best Albums Of 2026 (So Far)
StyleHow to Style Soccer Jerseys
MusicThe 15 Best Rap Verses Of 2026 (So Far)
MusicHip-Hop Media Power Ranking: The 2026 Edition
SneakersEvery Air Jordan Releasing in 2026
